# US 2008/0075730 A1 · Methods and compositions for treating biofilms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075730 A1
- Document ID: US20080075730A1
- Status: Published application
- Kind: A1
- Application number: 11/652,866
- Filed: 2007-01-12
- Published: 2008-03-27
- Earliest claimed: 2003-04-23
- Assignees: University Technologies International Inc.
- Inventors: Douglas Storey; Michael Parkins; Howard Ceri; James Davies; Merle Olson; Lyriam Marques
- Web page: https://patentgrep.com/patent/US20080075730A1

## CPC

- A01N 61/00: Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
- A01N 63/50: Isolated enzymes; Isolated proteins (peptides A01N37/46)
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to methods and compositions to regulate biofilm formation. In particular, the disclosure provides methods and compositions that relate to regulation of biofilm formation by modulating the GacA/GacS regulatory system as well as methods and compositions for inhibiting small colony variant formation and reversion of resistant bacteria to a wild-type phenotype.

## Claims

### Claim 1

A method of preventing biofilm formation comprising inhibiting the gacA/gacS regulatory system of an organism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the organism is P. aeruginosa.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibition is produced by antibodies to gacS and/or gacA.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibition is produced by an inhibitory nucleic acid to gacA and/or gacS.

### Claim 5

A method of inhibiting the production of small colony variants (SCVs) comprising contacting a bacterial population with an antagonist of the gacA/gacS regulatory system of the bacteria.

### Claim 6

A composition useful for preventing biofilm formation comprising an antagonist of a gacA/gacS regulatory system in a pharmaceutically acceptable form.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the antagonist is an antibody to gacS and/or gacA.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the antagonist is an inhibitory nucleic acid of gacA and/or gacS.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the compound is a small molecule which inhibits gacS and/or gacA.

### Claim 10

A method of treating an antimicrobial resistant biofilm, comprising:
contacting a resistant bacteria in the biofilm comprising a mutation in gacS with a gacS agonist, wherein the gacS agonist generates a wild-type phenotype in the resistant bacteria.

### Claim 11 (depends on 10)

The method of claim 10, wherein the resistant bacteria comprises a small colony variant.

### Claim 12 (depends on 10)

The method of claim 10, wherein the gacS agonist comprises a gacS polypeptide.

### Claim 13 (depends on 10)

The method of claim 10, wherein the gacS agonist comprises a gacS polynucleotide expressed in trans in the resistant bacteria.

### Claim 14 (depends on 10)

The method of claim 10, wherein the contacting is in vivo.

### Claim 15 (depends on 10)

The method of claim 10, wherein the contacting is in vitro.

### Claim 16 (depends on 15)

The method of claim 15, wherein the contacting is on a surface suspected of having a resistant bacteria.

### Claim 17 (depends on 14)

The method of claim 14, wherein the contacting in vivo is by topical administration.

### Claim 18 (depends on 10)

The method of claim 10, wherein the bacteria is gram negative.

### Claim 19 (depends on 10)

The method of claim 10, wherein the bacteria is selected from the group consisting of E. coli, P. aeruginosa, and S. typhimurium.

### Claim 20 (depends on 10)

The method of claim 10, wherein the agonist is administered in combination with at least one antibiotic.

### Claim 21 (depends on 20)

The method of claim 20, wherein the class of antibiotic is selected from the group consisting of aminoglycosides, penicillins, cephalosporins, carbapenems, monobactams, quinolones, tetracyclines, glycopeptides, chloramphenicol, clindamycin, trimethoprim, sulfamethoxazole, nitrofuirantoin, rifampin and mupirocin.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, netilmicin, t-obramycin, streptomycin, azithromycin, clarithromycin, erythromycin, erythromycin estolate/ethylsuccinate/gluceptatellactobionate/stearate, penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, ticarcillin, carbenicillin, mezlocillin, azlocillin, piperacillin, cephalothin, cefazolin, cefaclor, cefamandole, cefoxitin, cefuiroxime, cefonicid, cefmetazole, cefotetan, cefprozil, loracarbef, cefetamet, cefoperazone, cefotaxime, ceftizoxime, ceftriaxone, ceftazidime, cefepime, cefixime, cefpodoxime, cefsulodin, i-mipenem, aztreonam, fleroxacin, nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, cinoxacin, doxycycline, m-inocycline, tetracycline, vancomycin, and teicoplanin.

### Claim 23

A composition comprising a gacS agonist and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the gacS agonist comprises a gacS polynucleotide.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the gacS agonist is in a liposomal formulation.

### Claim 26 (depends on 24)

The composition of claim 24, wherein the gacS polynucleotide comprises a plasmid.

### Claim 27

A method comprising inhibiting biofilm formation, comprising:
contacting bacterial population with a gacS and/or gacA antagonist;
monitoring the bacterial population for the formation of a small colony variant;
contacting the small colony variant with a composition comprising gacS agonist.

### Claim 28 (depends on 27)

The method of claim 27, wherein the contacting is in vitro.

### Claim 29 (depends on 27)

The method of claim 27, wherein the contacting is in vivo.

### Claim 30 (depends on 27)

The method of claim 27, wherein the gacS and/or gacA antagonist comprise a polypeptide, inhibitory nucleic acid or small molecule that inhibits or reduces the production or activity of gacS and/or gacA.

### Claim 31 (depends on 27)

The method of claim 27, wherein the gacS agonist comprises a gacS polynucleotide.
